Clinical Trials Logo

Clinical Trial Summary

This trial will study how safely the tazemetostat works with other therapies in various hematological malignancies. Hematologic malignancies are cancers that most often begin in the bone marrow or lymph nodes where blood precursors are produced. They are often called blood cancers and fall into three categories: leukemia, lymphoma and myeloma. Tazemetostat has been found to be a safe and effective drug that works in patients with follicular lymphoma where the disease has come back after treatment (known as relapsed) and when other treatment no longer works (known as refractory). Combining tazemetostat with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.


Clinical Trial Description

This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective drug that works in patients with relapsed refractory (R/R) follicular lymphoma. Giving tazemetostat in combination with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05205252
Study type Interventional
Source Ipsen
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date December 22, 2021
Completion date July 5, 2023

See also
  Status Clinical Trial Phase
Completed NCT03096821 - Extended Analysis for Leukemia/Lymphoma Treatment
Recruiting NCT05956457 - PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma N/A
Active, not recruiting NCT03560882 - A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies Phase 1
Recruiting NCT03821519 - Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant Phase 1/Phase 2
Recruiting NCT05713214 - Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products
Active, not recruiting NCT03413800 - Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant Phase 2
Recruiting NCT05270096 - International Leukemia Target Board
Recruiting NCT03328078 - A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Phase 1/Phase 2
Recruiting NCT04327583 - Impact of the Coordinated Intervention of the Healthcare Facilities Pharmacist and the Dispensary Pharmacist on the Care Pathway for Cancer Patients Treated With Oral Therapy N/A